Association of Interleukin-17A with Biomarker Levels in Chronic Kidney Disease Patients
Article Sidebar
Main Article Content
Abstract
Chronic kidney disease (CKD) considers as a progressive condition correlated with systemic inflammation, which pays to complications such as cardiovascular disease and renal dysfunction. However, Interleukin-17A (IL-17A), a pro-inflammatory cytokine, plays a serious role in immune regulation and inflammation. This research examines the association of serum IL-17A and biomarkers (creatinine, Beta 2 Macroglobulin) levels in patients with CKD. A case-control study was conducted involving 60 CKD patients and 30 healthy controls at Imam Al-Hussein Medical-City hospital in Kerbala, Iraq, from August to October 2024. Blood and urine samples were collected from all participants, and IL-17A were tested utilizing an ELISA kit. The results stated significantly higher serum IL-17A levels in patients with CKD (24.56 ± 9.60 pg/mL) compared to controls (5.65 ± 1.84 pg/mL), p = 0.0007. Moreover, levels of creatinine in CKD patients (0.96 ± 0.51 mg/dL) were significantly elevated compared to controls (0.27 ± 0.10 mg/dL), p = 0.0002. These findings stated that elevated IL-17A levels are associated with CKD and may pay to chronic inflammation, exacerbating renal damage. Furthermore, serum creatinine and Beta 2 Macroglobulin remnants a reliable biomarker for assessing kidney function. Increased IL-17A levels in CKD patients could serve as potential biomarkers for disease progression and targets for therapeutic interventions aimed at mitigating inflammation and improving patient outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
L. Dan, F. Anthony, K. Dennis, H. Stephen, J. J., and L. Joseph, “Harrison’s Principles of Internal Medicine: Volumes 1 and 2, 18th Edition,” Mcgraw-hill, 2011.
F. M. RAFATI, F. Taghian, M. Pakfetrat, F. Daryanoosh, and H. Mohammadi, “The effect of aerobic training on the amount of GFR and excreted of creatinine in patients with chronic kidney,” 2012.
L. D. Bash, T. P. Erlinger, J. Coresh, J. Marsh-Manzi, A. R. Folsom, and B. C. Astor, “Inflammation, Hemostasis, and the Risk of Kidney Function Decline in the Atherosclerosis Risk in Communities (ARIC) Study,” Am. J. Kidney Dis., vol. 53, no. 4, 2009, doi: 10.1053/j.ajkd.2008.10.044.
S. M. H. Adel and H. Shahbazian, “Regression of left ventricular hypertrophy after successful renal transplantation among uremic patients,” 2003.
A. K. Singh, J. Himmelfarb, and L. A. Szczech, “Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia,” Journal of the American Society of Nephrology, vol. 20, no. 7. 2009. doi: 10.1681/ASN.2009040444.
F. M. Clement, S. Klarenbach, M. Tonelli, J. A. Johnson, and B. J. Manns, “The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis,” Archives of Internal Medicine, vol. 169, no. 12. 2009. doi: 10.1001/archinternmed.2009.112.
V. O. Leal, A. G. Delgado, M. Leite, W. E. Mitch, and D. Mafra, “Influence of Renal Function and Diet on Acid-Base Status in Chronic Kidney Disease Patients,” J. Ren. Nutr., vol. 19, no. 2, 2009, doi: 10.1053/j.jrn.2008.08.010.
C. M. Clase, B. A. Kiberd, and A. X. Garg, “Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: Results from the Third National Health and Nutrition Examination Survey (NHANES III),” Nephron - Clin. Pract., vol. 105, no. 4, 2007, doi: 10.1159/000100489.
C. P. Kovesdy and K. Kalantar-Zadeh, “Bone and mineral disorders in pre-dialysis CKD,” International Urology and Nephrology, vol. 40, no. 2. 2008. doi: 10.1007/s11255-008-9346-7.
H. Shahbazian, K. Mowla, H. Shahbazian, B. Peydayesh, and A. Ehsanpour, “Efficacy and safety of alendronate in the prevention of bone loss in renal transplant recipients,” Indian J. Nephrol., vol. 17, no. 2, 2007, doi: 10.4103/0971-4065.37022.
M. F. Elias, P. K. Elias, S. L. Seliger, S. S. Narsipur, G. A. Dore, and M. A. Robbins, “Chronic kidney disease, creatinine and cognitive functioning,” Nephrol. Dial. Transplant., vol. 24, no. 8, 2009, doi: 10.1093/ndt/gfp107.
S. Seifi and A. Mokhtari, “Serum IL-6 level and associated factors: Hemodialysis patients,” Tehran Univ. Med. J., vol. 66, no. 4, 2008.
F. Locatelli, B. Canaud, K. U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali, “Oxidative stress in end-stage renal disease: An emerging treat to patient outcome,” Nephrol. Dial. Transplant., vol. 18, no. 7, 2003, doi: 10.1093/ndt/gfg074.
K. Kalantar-Zadeh, T. A. Ikizler, G. Block, M. M. Avram, and J. D. Kopple, “Malnutrition-Inflammation Complex Syndrome in Dialysis Patients: Causes and Consequences,” American Journal of Kidney Diseases, vol. 42, no. 5. 2003. doi: 10.1016/j.ajkd.2003.07.016.
E. Razeghi, A. Aazaripour, and others, “Evaluation of variability of acute phase proteins in hemodialysis patients,” Tehran Univ. Med. Sci. J., vol. 64, no. 9, pp. 78–82, 2006.
K. Kalantar-Zadeh, G. Block, C. J. McAllister, M. H. Humphreys, and J. D. Kopple, “Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients,” in American Journal of Clinical Nutrition, 2004, vol. 80, no. 2. doi: 10.1093/ajcn/80.2.299.
J. C. Korevaar, J. G. Van Manen, F. W. Dekker, D. R. De Waart, E. W. Boeschoten, and R. T. Krediet, “Effect of an increase in C-reactive protein level during a hemodialysis session on mortality,” J. Am. Soc. Nephrol., vol. 15, no. 11, 2004, doi: 10.1097/01.ASN.0000143744.72664.66.
Q. Yao, B. Lindholm, and P. Stenvinkel, “Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients,” Hemodialysis International, vol. 8, no. 2. 2004. doi: 10.1111/j.1492-7535.2004.01085.x.
E. Lacson and N. W. Levin, “C-reactive protein and end-stage renal disease,” Seminars in Dialysis, vol. 17, no. 6. 2004. doi: 10.1111/j.0894-0959.2004.17604.x.
C. Wanner and T. Metzger, “C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients,” Nephrol. Dial. Transplant., vol. 17, no. SUPPL. 8, 2002, doi: 10.1093/ndt/17.suppl_8.29.
B. Seruga, H. Zhang, L. J. Bernstein, and I. F. Tannock, “Cytokines and their relationship to the symptoms and outcome of cancer,” Nature Reviews Cancer, vol. 8, no. 11. 2008. doi: 10.1038/nrc2507.
S. F. Maier and L. R. Watkins, “Cytokines for Psychologists: Implications of Bidirectional Immune-to-Brain Communication for Understanding Behavior, Mood, and Cognition,” Psychol. Rev., vol. 105, no. 1, 1998, doi: 10.1037/0033-295X.105.1.83.
C. Albanesi, A. Cavani, and G. Girolomoni, “IL-17 Is Produced by Nickel-Specific T Lymphocytes and Regulates ICAM-1 Expression and Chemokine Production in Human Keratinocytes: Synergistic or Antagonist Effects with IFN-γ and TNF-α,” J. Immunol., vol. 162, no. 1, 1999, doi: 10.4049/jimmunol.162.1.494.
N. Melzer et al., “A β-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis,” PLoS One, vol. 3, no. 9, 2008, doi: 10.1371/journal.pone.0003149.
T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, “Interleukin-17 family and IL-17 receptors,” Cytokine & growth factor Rev., vol. 14, no. 2, pp. 155–174, 2003.
X. W. Zhu et al., “IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines,” Breast Cancer Res., vol. 10, no. 6, 2008, doi: 10.1186/bcr2195.
T. Pischon, F. B. Hu, K. M. Rexrode, C. J. Girman, J. A. E. Manson, and E. B. Rimm, “Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men,” Atherosclerosis, vol. 197, no. 1, 2008, doi: 10.1016/j.atherosclerosis.2007.06.022.
O. Ortega et al., “Significance of high C-reactive protein levels in pre-dialysis patients,” Nephrol. Dial. Transplant., vol. 17, no. 6, 2002, doi: 10.1093/ndt/17.6.1105.
A. Jalili, A. A. Ravasi, S. Choobineh, A. Alidadi, R. Suri, and H. Khazaei, “Serum Interleukin-17 Alterations in Patients With Chronic Kidney Disease Undergoing Eight Weeks of Aerobic Training,” Int. J. Basic Sci. Med., vol. 6, no. 2, 2021, doi: 10.34172/ijbsm.2021.12.
“The Effect of Some Biochemical and Physiological Parameters in Iraqi Patients with Renal Failure,” J. Biol. Agric. Healthc., 2020, doi: 10.7176/jbah/10-14-04.
A. Habib, R. Ahmad, and S. Rehman, “Hematological changes in patients of chronic renal failure and the effect of hemodialysis on these parameters,” Int. J. Res. Med. Sci., vol. 5, no. 11, 2017, doi: 10.18203/2320-6012.ijrms20174959.
S. Singh and S. Bhatta, “Biochemical and hematological parameters in chronic kidney disease,” J. Manmohan Meml. Inst. Heal. Sci., vol. 4, no. 1, 2018, doi: 10.3126/jmmihs.v4i1.21132.
N. Singhal, D. R. D. Mathur, D. A. K. Bhargava, and D. D. Gupta, “Comparative study of renal function test and thyroid hormone in chronic kidney disease,” Int. J. Med. Res. Rev, vol. 8, no. 6, pp. 427–431, 2020.